Topical Platform Technology

Skin pain should be treated where it occurs

Auxesis Pharma develops topical treatments designed to act directly at the source of pain and irritation in the skin.

Our technology is based on a stabilized liquid form of acetylsalicylic acid, developed for precise local application without unnecessary systemic exposure.

The platform forms the foundation for ASA.P® and several future products within human medicine, aesthetic dermatology, cosmeceuticals and veterinary medicine.

Vetenskapsbaserad utveckling
Topikal behandling
Lokal och riktad verkan
Topical application of ASA.P®
The first product on the platform

ASA.P® – local treatment of skin pain

ASA.P® is the first product being developed on Auxesis Pharma’s topical technology platform. It is designed to treat pain and irritation directly in the affected area of the skin.

The stabilized liquid form of ASA penetrates locally, reaches and blocks COX signals at the source of pain and remains where it is needed.

  • Local application directly to the skin
  • Non-systemic action
  • Targeted treatment at the source of pain
  • Developed for rapid effect
Vår produktportfölj

Två affärsområden. En gemensam teknologiplattform.

Auxesis utvecklar produkter inom läkemedel och dermatologi med fokus på lokal behandling, användarvänliga format och tydlig nytta för patienter, konsumenter och vårdpersonal.

PHARMA
01

PHARMA

Läkemedelsutveckling inom topikal smärtblockering, dermatologi och veterinärmedicin.

Upptäck PHARMA
DERMATOLOGY
02

DERMATOLOGY

Dermatologiska och cosmeceutiska produkter för behandling, eftervård och professionell hudvård.

Upptäck DERMATOLOGY
Development pipeline

One technology platform. Multiple future products.

Discover our development projects within dermatology, aesthetic medicine, cosmeceuticals and veterinary medicine.

Explore our pipeline
Skin representing local treatment of pain and irritation

Broad areas of application

ASA.P® is being developed for the local treatment of common conditions where pain, stinging and irritation occur directly in the skin.

Examples of local skin pain:

Mosquito bites

Targeted local treatment of pain, itching, swelling and irritation.

Jellyfish stings

Developed for the local treatment of burning pain, stinging and skin irritation.

Wasp stings

Local treatment for pain, burning sensation, redness and swelling.

Hives and stinging nettles

Targeted treatment of local stinging, itching and skin irritation.

Sun rash

Local treatment of pain, stinging and irritation following sun exposure.

Minor skin irritations

Precise application directly to the area where pain and irritation occur.

External developments and medical knowledge

Skin-related conditions requiring local treatment

ASA.P® is being developed for targeted application directly to the skin. Here, we present external medical sources and articles describing conditions where pain, itching and irritation occur locally.

Dagbladet

Skin condition spreading in Norway

A current example of how skin-related conditions can affect many people and create a need for accessible local treatment options.

Praktisk Medicin

Swimmer’s itch and cercarial dermatitis

Medical information about local skin reactions involving itching and irritation that may occur after swimming in freshwater.

2025–Validation of the pharmaceutical formulation

The pharmaceutical formulation was evaluated with regard to solubility, skin penetration, permeability and stability, among other factors.

2026–Clinical trial authorised

The Swedish Medical Products Agency has authorised a clinical trial for ASA.P®. The clinical studies are planned to begin in Uppsala during autumn 2026.

2027–2028–Continued clinical and regulatory development

The results from the clinical studies will form the basis for continued product development, regulatory activities and preparations for future market introduction.

2028–2029–Commercial expansion

The objective is to prepare for launch, partnerships and geographical expansion for ASA.P® and related products based on the platform technology.

Future pipeline–Multiple products from the same technology platform

The platform enables development projects within human medicine, veterinary medicine, dermatology, aesthetic medicine and cosmeceuticals.

One technology platform. Multiple future products.

Auxesis Pharma is developing a growing portfolio of topical products for the local treatment of pain, irritation and skin-related conditions.

In addition to ASA.P®, the development pipeline includes projects within pharmaceuticals, veterinary medicine, aesthetic dermatology and cosmeceuticals, including Dermexa™, Cutivelle™, Lenvée™ and CoxyPet®.

Explore our pipeline
Auxesis Pharma’s development of topical products